{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:22:48Z","timestamp":1771953768265,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,7,8]],"date-time":"2003-07-08T00:00:00Z","timestamp":1057622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Advanced seminoma is a rare clinicopathologic entity. To the authors' knowledge, very few sizeable reports published to date have studied the outcome of patients with advanced seminoma after first\u2010line and salvage therapy, and few have dealt with prognostic factors initially or in patients with recurrent disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The records of 145 men with advanced seminoma who were treated with cisplatin\u2010based first\u2010line chemotherapy regimens were reviewed. Six patient characteristics, including age, prior radiotherapy, primary tumor site, initial serum lactate dehydrogenase and human chorionic gonadotropin levels, and disease stage, were studied as initial prognostic factors. In patients with recurrent disease, outcome according to the site of recurrence and the salvage treatment was also reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A complete response was obtained in 130 patients (90%) after cisplatin\u2010based first\u2010line chemotherapy, and the 5\u2010year overall survival rate was 81% (95% confidence interval [95% CI], 73\u201387%). Nonpulmonary visceral metastasis at diagnosis was the only initial adverse prognostic factor. Thirty\u2010one patients (21%) developed recurrent disease. Recurrence in the liver or the central nervous system was a major adverse prognostic factor, with a 5\u2010year overall survival rate of 7% (95% CI, 1\u201332%), compared with 58% (95% CI, 33\u201379%) in patients who had lymph node, lung, or bone recurrences. The only durable complete remission after a liver recurrence was obtained with high\u2010dose chemotherapy followed by autologous stem cell transplantation. All 12 patients who were treated for primary mediastinal seminoma with cisplatin\u2010based chemotherapy alone were long\u2010term disease free survivors.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Overall, the prognosis of patients with advanced seminoma was good after cisplatin\u2010based, first\u2010line chemotherapy. Metastasis in the liver or the central nervous system, initially or at recurrence, is currently the only proven adverse prognostic factor. Cancer 2003;98:745\u201352. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11574<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11574","type":"journal-article","created":{"date-parts":[[2003,8,5]],"date-time":"2003-08-05T11:47:11Z","timestamp":1060084031000},"page":"745-752","source":"Crossref","is-referenced-by-count":55,"title":["Advanced seminoma\u2014Treatment results and prognostic factors for survival after first\u2010line, cisplatin\u2010based chemotherapy and for patients with recurrent disease"],"prefix":"10.1002","volume":"98","author":[{"given":"Dany","family":"Gholam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Jose","family":"Terrier\u2010Lacombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Jan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Theodore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,7,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(85)90030-6"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(89)90334-9"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(86)80195-5"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.290"},{"key":"e_1_2_6_6_2","first-page":"17","article-title":"Primary mediastinal seminoma","volume":"12","author":"Polansky SM","year":"1979","journal-title":"Am J Radiol."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10021-1"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.10.1325"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.8.1212"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)43376-3"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.1.120"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.594"},{"key":"e_1_2_6_13_2","first-page":"353","article-title":"Cisplatin\u2010based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience","volume":"34","author":"Culine S","year":"1998","journal-title":"Eur J Cancer."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.121"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1427"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2546"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000121089"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950701)76:1<154::AID-CNCR2820760126>3.0.CO;2-W"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00425-X"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1985.141"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/oxfordjournals.annonc.a058046","article-title":"VAB\u20106 and cisplatin\u2010cyclophosphamide combinations in the treatment of metastatic seminoma patients: the USSR experience","volume":"2","author":"Tjulandin SA","year":"1991","journal-title":"Ann Oncol."},{"key":"e_1_2_6_22_2","first-page":"186","article-title":"Prognostic factors in patients with advanced metastatic seminoma treated with either single agent carboplatin or cisplatin\u2010based combination chemotherapy: a meta\u2010analysis of prospective European trials","volume":"21","author":"Bokemeyer C","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.167.3.3129752"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011201)92:11<2778::AID-CNCR10125>3.0.CO;2-S"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/106689690201000105"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.297"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2277"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1173"},{"key":"e_1_2_6_29_2","first-page":"180","article-title":"High\u2010dose therapy in the salvage treatment of patients failing first\u2010line platinum chemotherapy for advanced germ cell tumors; first results of a prospective randomized trial of the European Group for Blood and Marrow Transplantation: IT\u201094 study","volume":"21","author":"Rosti G","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703623"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11574","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:16:50Z","timestamp":1760293010000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11574"}},"subtitle":["<i>A single\u2010institution experience in 145 patients<\/i>"],"short-title":[],"issued":{"date-parts":[[2003,7,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,8,15]]}},"alternative-id":["10.1002\/cncr.11574"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11574","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,8]]}}}